CClinicalTrials.gg
CompletedNCT05992025DIG-MGUpdated Mar 30, 2025

Digital Phenotyping and Lifestyle Intervention in Patients with Myasthenia Gravis

An interventional study of Physical activity and Sleep hygiene in Myasthenia Gravis, sponsored by Uppsala University. Completed at 1 site in Sweden. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-03-30.

Sponsored by Uppsala University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
83
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Study summary

Myasthenia Gravis (MG) is a chronic autoimmune neurological disorder where an antibody attack of muscle receptors causes fatigable skeletal muscle weakness. In addition to fatigue, several MG patients experience general fatigue. Small supervised studies during 12 weeks of physical exercise interventions have indicated safety and beneficial neuromuscular outcomes in MG patients. Longer and unsupervised studies are required to obtain guidelines for physical activity in MG patients. Further, the development of smart rings enables remote digital supervision of physical activity, sleep, and biological parameters such as heart frequency, number of steps, and temperature. These parameters could add to the lack of biomarkers in MG. The project design is a randomized controlled trial with a lifestyle intervention to improve fatigue in the autoimmune neuromuscular disease Myasthenia Gravis (MG). The intervention includes digital group counseling regarding physical activity, sleep, general health, and digital follow-up with a "smart ring" (OURA).

Read the detailed description

The cohort is Myasthenia Gravis (MG) patients in Sweden. The primary research question is: can digital lifestyle intervention in an online-group format improve fatigue as measured by MG-ADL in MG patients by at least 30%? Secondary research question: can lifestyle intervention improve fatigue as measured by FSS in MG by at least 30%?

The primary outcome measure is MG-ADL; the secondary outcome measures include general fatigue (fatigue severity scale and Chalder´s fatigue scale). Exploratory outcome measures include OURA-ring-based markers, including heart rate variability, temperature fluctuations, and sleep and activity parameters. These will be collected throughout the entire study period for 30 weeks.

Analysis of serum biomarkers miR-150-5p and miR-30e-5p and inflammatory proteins found upregulated in MG will be included. Clinical data at baseline: antibody status, electrophysiology, MG Composite Scale (MGC), and clinical data at follow-up visits (medications, MGC), etc., are extracted from the medical charts and the Swedish MG registry

Inclusion criteria:

  • An MG diagnosis for at least six months before entry into the study.
  • Both patients with ocular and generalized MG are allowed to participate.
  • For practical reasons, participants need to understand Swedish.

Exclusion criteria:

  • Participation in another clinical trial in the past 6 months.
  • Disease duration less than 6 months.
  • Contraindications to physical activity: unstable coronary syndrome or myocardial infarction within the preceding three months, respiratory failure (vital capacity \< 70% predicted value) or cardiac failure (ejection fraction \< 50% predicted value), concomitant neuromuscular diseases, disabling rheumatological disease (> 80% disability on the Barthel scale), chronic pain or disabling orthopedic conditions, hospitalization in the last three months for a serious medical or surgical condition, anemia (hematocrit \< 30%), stroke within the previous year.
  • MG patients already performing a moderate-intensity physical activity of 150min or more per week, i.e., one of the target interventions.
  • Pregnancy.

Each participant is enrolled in the study for 7 months, and 26 persons are randomized to one of the following 3 groups:

  • Group 1; no intervention, observation with the OURA ring.
  • Group 2: 12 weeks of physical activity guidance with short discussions via digital meetings regularly. They will conduct at least 150 minutes per week of moderate-intensity exercises. Brisk walks are the primary choice of activity; alternatively, swimming, cycling, or dancing to the physical exertion according to the Borg scale can be performed.
  • Group 3: 12 weeks of sleep exercises. The lifestyle intervention of sleep will be delivered via an online group, with recommended home practices between sessions. Topics covered will include sleep education, sleep hygiene, and practices to improve sleep quality.

The study is digital and will use the platform "minforskning.se", which is validated according to GCP-GAMP5 and has the potential to collect digital consent forms.

02

Conditions studied

  • Myasthenia Gravis

Keywords

  • lifestyle intervention
  • fatigue
  • OURA
  • physical activity
03

In context

Myasthenia Gravis

324 studies on the registry are indexed under Myasthenia Gravis; 146 are open to participants now.

This study's enrollment of 83 is above the median of 44 across 212 interventional studies indexed under Myasthenia Gravis.

Browse Myasthenia Gravis studies →

Lead sponsor

Uppsala University is the lead sponsor of 381 studies on the registry; 84 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • The MG disease status must be stable for at least six months before entry into the study; thus, the duration of the disease must be at least six months.
  • Both patients with ocular and generalized MG are allowed to participate.
  • For practical reasons, participants need to be able to understand fully and communicate in Swedish.

Exclusion criteria

Exclusion Criteria:

  • Participation in another clinical trial in the past 6 months.
  • Disease duration less than 6 months.
  • Contraindications to physical activity: unstable coronary syndrome or myocardial infarction within the preceding three months, respiratory failure (vital capacity \< 70% predicted value) or cardiac failure (ejection fraction \< 50% predicted value), concomitant neuromuscular diseases, disabling rheumatological disease (> 80% disability on the Barthel scale), chronic pain or disabling orthopedic conditions, hospitalization in the last three months for a serious medical or surgical condition, anemia (hematocrit \< 30%), stroke within the previous year.
  • MG patients already performing moderate-intensity physical activity of 150min or more per week, i.e., one of the target interventions.
  • Pregnancy.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
83 participants (actual)

Study arms

  • No intervention
    Observation

    Observation with the OURA ring and no digital meetings. The participants are offered delayed randomization after the study period. This group's outcome from the delayed randomization will be for the exploratory analysis, i.e., not in the primary analysis.

  • Experimental
    Physical activity

    12 weeks of physical activity guidance with short discussions via online group meetings according to a schedule. The participants in this arm will conduct moderate-intensity exercises for at least 150 minutes per week. Brisk walks are the primary choice of activity; alternatively, swimming, cycling, or dancing to the physical exertion according to the Borg scale can be performed.

    Behavioral: Physical activity

  • Active comparator
    Sleep hygiene intervention

    12 weeks of sleep exercises. The lifestyle intervention of sleep will be delivered via an online group, with recommended home practices between sessions. Topics covered will include sleep education, sleep hygiene, and practices to improve sleep quality.

    Behavioral: Sleep hygiene

Interventions

  • BehavioralPhysical activity

    Intervention with physical activity more than 150 minutes of medium to high intensity per week.

  • BehavioralSleep hygiene

    Intervention with sleep hygiene to optimize sleep duration and quality.

06

What researchers measure

Primary outcomes

  1. Myasthenia Gravis-Activities of Daily Living (MG-ADL)

    Subjective assessment of MG-related fatiguability. A person's score can range from zero (normal) to 24 (most severe).

    Time frame: 7 months

Secondary outcomes

  1. Fatigue Severity Scale (FSS)

    The Fatigue Severity Scale (FSS) ranges from 0 (least fatigue) to 63 (maximum fatigue).

    Time frame: 7 months

  2. Chalder Fatigue Scale

    The Chalder Fatigue Scale ranges from 0 (least fatigue) to 33 (maximum fatigue)

    Time frame: 7 months

Other outcomes

  1. Heart rate variability

    Heart rate variability is measured with the OURA ring.

    Time frame: 7 months

  2. Activity pattern

    Number of steps and minutes in moderate and high intensity activity is measured by the OURA ring.

    Time frame: 7 months

  3. Percentage of deep sleep

    The OURA ring measures the sleep stages, including time and percentage for deep sleep every night.

    Time frame: 7 months

  4. Circulating miRNA in serum

    Changes in miR-150-5p and miR-30e-5p in serum samples.

    Time frame: 7 months

  5. Olink Target 96 Inflammation panel of cytokines

    Changes in cytokine NPX protein values (log2 scaled) using Proximity Extension Assay (PEA) technology in serum samples

    Time frame: 7 months

07

Study locations

1 site
  • Uppsala University
    Uppsala, 75185, Sweden
08

References and documents

Individual participant data

Plan to share: No — Not relevant.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05992025
Lead sponsor
Uppsala University
Responsible party
Sponsor
First posted
Aug 15, 2023
Start date
Jul 10, 2023
Primary completion
Aug 15, 2024
Completion
Mar 15, 2025
Last update
Mar 30, 2025

Study contacts

Anna Rostedt Punga, MD, PhD
principal investigator · Uppsala University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion